ASCO 2017: Stereotactic ablative radiotherapy for the treatment of oligometastatic prostate cancer

Over the past several years, there has been increased interest in treatment of oligometastatic sites for patients with prostate cancer. At the prostate cancer poster session at the 2017 ASCO annual meeting, Dr. Tran presented their findings of stereotactic ablative radiation therapy for treatment of oligometastatic prostate cancer. Stereotactic ablative radiotherapy (SABR) is highly focused, high-dose radiation that is well suited for treatment of oligometastases.
Uro Today